EUROPEAN UROLOGY, vol.77, no.4, pp.494-500, 2020 (SCI-Expanded)
Background: LATITUDE, a randomized, double-blind trial, compared abiraterone acetate and prednisone (AAP) + androgen deprivation therapy (ADT) versus placebo (PBO) + ADT in high-risk metastatic castration-sensitive prostate cancer (mCSPC).